BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $23
BofA Securities analyst Jason Zemansky maintains $Arcus Biosciences(RCUS.US)$ with a hold rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 61
Hold Rating on Arcus Biosciences Amid TIGIT Inhibitor Uncertainties
Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $25
Barclays analyst Peter Lawson maintains $Arcus Biosciences(RCUS.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 45.0% and
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
Arcus up 4% Following Merck Welireg Kidney Cancer Data
Arcus Biosciences, Inc.'s (NYSE:RCUS) Business And Shares Still Trailing The Industry
Infinimmune Appoints Dr. Tim Sullivan as Chief Business Officer
Express News | Arcus Biosciences: Facility Adds Operational Flexibility & Provides Funding for Recently Announced Phase 3 Peak-1 Study for Casdatifan.
Arcus Biosciences Secures Up to $250 Million Term Loan Facility From Hercules Capital
Express News | Arcus Biosciences Secures up to $250 Million Term Loan Facility From Hercules Capital
Arcus Biosciences Announces New Employment Inducement Grants
Truist Financial Keeps Their Buy Rating on Arcus Biosciences (RCUS)
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Leerink Partners Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $46
Leerink Partners analyst Daina Graybosch maintains $Arcus Biosciences(RCUS.US)$ with a buy rating, and sets the target price at $46.According to TipRanks data, the analyst has a success rate of 31.1%
Arcus Biosciences: A Strong Buy on Promising Drug Pipeline and Anticipated Clinical Milestones
Express News | Arcus Biosciences Inc : Leerink Partners Raises Target Price to $46 From $35
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Taysha Gene Therapies (TSHA) and Y-Mabs Therapeutics (YMAB)
Truist Financial Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
Truist Financial analyst Asthika Goonewardene maintains $Arcus Biosciences(RCUS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 30.0% and a total average return
Arcus Biosciences Second Quarter 2024 Earnings: Beats Expectations